Tonix Pharmaceuticals TNX-102 SL Fibromyalgia 2024 Biotech Showcase

Tonix Pharmaceuticals presents its CNS-focused pipeline including TNX-102 SL, a sublingual formulation in Phase 3 development for fibromyalgia management with New Drug Application filing expected in H2'24. The company markets migraine treatments Zembrace and Tosymra, while advancing preclinical and clinical stage candidates including a biologic cocaine antidote with FDA Breakthrough Therapy Designation.